Journal Article

Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

van der Ploeg, Lex, Lynch, David R., Omidvar, Omid, Vogel, Adam P., Heerinckx, Frederic, Zesiewicz, Theresa, Midei, Mark, Subramony, Sub, Mathews, Katherine D., Milner, Peter, Litterman, Nadia, Perlman, Susan, Krtolica, Ana

2023

Overview

Objectives Friedreich ataxia is (FRDA) an autosomal recessive neurodegenerative disorder associated with intrinsic oxidative damage, suggesting that decreasing lipid peroxidation (LPO) might ameliorate disease progression. The present study tested the ability of RT001, a deuterated form of linoleic acid (D2-LA), to alter disease severity in patients with FRDA in a double-blind placebo-controlled trial. Methods Sixty-five subjects were recruited across six sites and received either placebo or active drug for an 11-month study. Subjects were evaluated at 0, 4, 9, and 11 months, with the primary outcome measure being maximum oxygen consumption (MVO2) during cardiopulmonary exercise testing (CPET). A key secondary outcome measure was a composite statistical test using results from the timed 1-min walk (T1MW), peak workload, and MVO2. Results Forty-five subjects completed the protocol. RT001 was well tolerated, with no serious adverse events related to drug. Plasma and red blood cell (RBC) membrane levels of D2-LA and its primary metabolite deuterated arachidonic acid (D2-AA) achieved steady-state concentrations by 4 months. No significant changes in MVO2 were observed for RT001 compared to placebo. Similarly, no differences between the groups were found in secondary or exploratory outcome measures. Post hoc evaluations also suggested minimal effects of RT001 at the dosages used in this study. Interpretations The results of this study provide no evidence for a significant benefit of RT001 at the dosages tested in this Friedreich ataxia patient population.

• Publisher: Springer Berlin Heidelberg,Springer Nature B.V
• Subject: Arachidonic acid / Ataxia / Disease progression / Double-Blind Method / Double-blind studies / Drug dosages / Erythrocytes / Ferroptosis / Friedreich Ataxia - drug therapy / Friedreich's ataxia / Hereditary diseases / Humans / Linoleic acid / Linoleic Acid - therapeutic use / Linoleic Acids - therapeutic use / Lipid peroxidation / Medicine / Medicine & Public Health / Neurodegenerative diseases / Neurology / Neuroradiology / Neurosciences / Original Communication / Oxygen consumption / Placebos / Walking